Treatment Algorithms in The Modern Psoriasis Landscape

The treatment of moderate to severe psoriasis (PsO) has been transformed by biologic agents targeting the IL-23/IL-17 axis — a cytokine cascade now well established as central to psoriatic inflammation. Agents including risankizumab, guselkumab, bimekizumab, and ixekizumab have demonstrated the capacity to produce deep skin clearance, with substantial proportions of patients achieving PsO Area and Severity Index (PASI) 90 and PASI 100 responses in both pivotal trials and real-world settings. These agents currently define the efficacy ceiling in PsO management, and for patients in whom rapid, profound clearance is the primary clinical goal, advanced biologics remain the standard against which all other options are measured. Long-term registry and real-world data across multiple international and North American datasets have reinforced this position, consistently showing that IL-23 inhibitors in particular exhibit superior drug survival compared with other biologic classes.

The oral treatment landscape in psoriasis has historically played a secondary role—generally reserved for patients with milder disease or those unwilling or unable to use injectable therapies, given efficacy ceilings well below those achieved with advanced biologics. While newer oral agents have expanded options within this class, these outcomes remain variable and have not consistently matched the speed, depth, or reliability demonstrated by established injectable IL‑23 biologics across broader patient populations. As with other oral therapies, convenience factors such as once‑daily dosing and avoidance of injections are frequently cited advantages; however, these attributes must be weighed against a more limited evidence base, particularly with respect to long‑term durability, consistency of high‑level clearance, and performance in more severe or refractory disease.

Importantly, oral agents as a class lack the extensive multi‑year efficacy and safety data now available for biologic IL‑23 therapies, which continue to set the benchmark for sustained disease control in moderate‑to‑severe PsO. As such, oral therapies—including newer entrants—are best considered within a defined niche rather than as direct substitutes for advanced biologics. In this Special Report segment, Bruce Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine, characterizes the current landscape as one of expanded choice rather than therapeutic replacement. The emergence of additional oral options has not altered the central role of biologics but instead offers an alternative for select patients whose disease severity, treatment goals, or preferences align with the efficacy profile of an oral agent. Strober frames treatment selection as a nuanced decision driven by mechanism, durability expectations, comorbidities, and real‑world experience—reinforcing a framework in which oral and injectable therapies are differentiated by role and clinical appropriateness rather than viewed as equivalently powerful options.